- WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19
- People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection
- Cybin is on a mission to revolutionize mental healthcare
A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental health, which has been rocked by the COVID-19 pandemic, is only increasing (https://ibn.fm/hzmXq). Cybin (NEO: CYBN) (NYSE American: CYBN) is focused on meeting that need and is committed to finding even more effective ways to help those struggling with mental health issues.
“The COVID-19 pandemic has disrupted or halted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey,” a WHO news release reported. “The survey of 130 countries provides the first global data showing the devastating impact of COVID-19 on access to mental health services and underscores the urgent need for increased funding.”
The release goes on to note that the underfunding of mental health issues is nothing new. “Prior to the pandemic, countries were spending less than 2% of their national health budgets on mental health, and struggling to meet their populations’ needs,” the release pointed out. “And the pandemic is increasing demand for mental health services. Bereavement, isolation, loss of income and fear are triggering mental health conditions or exacerbating existing ones.
“Many people may be facing increased levels of alcohol and drug use, insomnia, and anxiety. Meanwhile, COVID-19 itself can lead to neurological and mental complications, such as delirium, agitation, and stroke. People with pre-existing mental, neurological or substance use disorders are also more vulnerable to SARS-CoV-2 infection — they may stand a higher risk of severe outcomes and even death.”
The report quotes the director-general of WHO, Dr. Tedros Adhanom Ghebreyesus. “Good mental health is absolutely fundamental to overall health and well-being. COVID-19 has interrupted essential mental health services around the world just when they’re needed most. World leaders must move fast and decisively to invest more in life-saving mental health programs — during the pandemic and beyond.”
The survey only underscores the work that Cybin is doing. This game-changing company is keenly aware that more than 700 million people around the world are impacted with some sort of mental illness, addiction or eating disorder, and the company is on a mission to revolutionize mental healthcare.
The innovative organization is focused on leveraging its expertise in the psychedelic therapeutic space to deliver proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. “We are focused on addressing the mental health crisis and transforming the treatment landscape,” the company’s website states. “To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients.”
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment